指南与共识呼吸衰竭与机械通气重症综合管理与镇静镇痛

慢性阻塞性肺疾病患者肺曲霉病诊治专家共识

[Expert consensus on the diagnosis and treatment of pulmonary aspergillosis in patients with chronic obstructive pulmonary disease].
指南 / 共识 · Zhonghua Jie He He Hu Xi Za Zhi · 2024-01-01
一句话结论共识推荐对疑似侵袭性肺曲霉病的慢阻肺患者行HRCT,不能除外时查痰和BALF真菌学;伏立康唑、艾沙康唑、泊沙康唑为一线治疗,疗程至少6-12周。

慢阻肺患者肺曲霉病发病率上升,可表现为侵袭性肺曲霉病(IPA)、慢性肺曲霉病(CPA)和变应性支气管肺曲霉病(ABPA),各形式间可互相转换甚至并存。共识基于循证证据和我国临床实践,对慢阻肺伴肺曲霉病诊治中的重要问题提出推荐意见并构建临床诊疗路径。多数推荐证据水平低,共识未列出证据等级,强推荐和弱推荐分别表述为「推荐」和「建议」。共识涵盖IPA、CPA、曲霉致敏及糖皮质激素使用四部分。

要点

  • 疑似慢阻肺伴IPA者推荐行高分辨率胸部CT(HRCT);CT不能除外IPA时,推荐行痰和支气管肺泡灌洗液(BALF)真菌学检查。
  • 慢阻肺伴IPA一线治疗推荐伏立康唑、艾沙康唑和泊沙康唑;棘白菌素类和两性霉素B可作为替代选择;疗程至少6-12周。
  • 慢阻肺伴CPA一线治疗推荐口服伊曲康唑溶液或伏立康唑片;疗程至少6个月,慢性空洞性肺曲霉病(CCPA)患者至少9个月。
  • 不推荐仅根据咳嗽、发热、呼吸困难等临床症状在慢阻肺患者中经验性启动抗真菌治疗。
  • 慢阻肺伴曲霉致敏者不推荐常规启动抗真菌治疗;符合ABPA诊断标准者建议抗真菌治疗,疗程一般3-6个月。

适用人群与场景

  • 慢性阻塞性肺疾病(慢阻肺)患者,涵盖侵袭性肺曲霉病(IPA)、慢性肺曲霉病(CPA)和变应性支气管肺曲霉病(ABPA)等不同形式。
  • 重症患者:收治ICU及呼吸衰竭者,对广谱抗生素治疗无反应且影像学符合IPA。
  • 合并曲霉致敏的慢阻肺患者:规范慢阻肺治疗后仍持续喘息,或符合ABPA诊断标准者。
  • 稳定期慢阻肺合并CPA患者(用于糖皮质激素使用建议)。

诊断标准与关键阈值

  • 慢阻肺患者急性感染病程超过10天时,推荐检测外周血曲霉特异性IgG抗体以辅助IPA诊断,尤其适用于无法获取BALF者。
  • 慢阻肺患者出现难治性喘息和/或肺功能快速下降时,推荐评估曲霉致敏,包括曲霉特异性IgE、皮肤曲霉抗原试验、曲霉特异性IgG、总IgE、血嗜酸性粒细胞计数和痰液检查。
  • 符合ABPA诊断标准者建议抗真菌治疗。

处置流程与药物剂量

  • 疑似IPA者推荐行HRCT;CT不能除外IPA时,推荐行痰和BALF真菌学检查。
  • 慢阻肺患者使用广谱抗生素和全身糖皮质激素后仍有呼吸困难等呼吸道症状且胸部CT见肺部浸润影时,推荐行支气管镜和BALF曲霉相关检查。
  • 疑似IPA但诊断存疑者,推荐行组织病理学检查。
  • 慢阻肺伴IPA:推荐伏立康唑、艾沙康唑、泊沙康唑为一线治疗;棘白菌素类和两性霉素B可作为替代选择;抗真菌治疗至少持续6-12周,疗程根据临床症状、肺部影像学和微生物学检查结果确定,病灶明显吸收稳定及消除相关危险因素是停药的重要参考。
  • 慢阻肺伴CPA:推荐胸部CT扫描和动态观察;推荐检测外周血曲霉特异性IgG抗体;常规方法难以诊断或需进一步鉴别者推荐肺组织病理学检查;一线治疗推荐口服伊曲康唑溶液或伏立康唑片,口服艾沙康唑胶囊或泊沙康唑肠溶片可作为替代;三唑类治疗失败、耐药或不耐受时,建议静脉棘白菌素类或两性霉素B(脱氧胆酸盐或脂质制剂)作为二线治疗;抗真菌治疗至少6个月,CCPA患者至少9个月。
  • CPA伴空洞与支气管腔相通者,全身抗真菌治疗无效或因不良反应不能耐受且手术不可行时,专家组建议考虑雾化吸入两性霉素B及空洞内注射两性霉素B或唑类(伏立康唑、伊曲康唑)以控制反复咯血。
  • 慢阻肺伴曲霉致敏:不推荐常规启动抗真菌治疗;符合ABPA诊断标准者建议抗真菌治疗,最常用口服伊曲康唑溶液,也可选择伏立康唑、艾沙康唑和泊沙康唑肠溶片等其他唑类,疗程一般3-6个月。
  • 糖皮质激素:慢阻肺急性加重继发IPA或亚急性侵袭性肺曲霉病者,专家组建议控制糖皮质激素使用;合并CPA且以喘息为主急性加重者,建议在抗真菌治疗基础上考虑短期低剂量糖皮质激素控制症状;慢阻肺急性加重的糖皮质激素使用建议以外周血嗜酸性粒细胞计数为指导;稳定期慢阻肺合并CPA者推荐避免全身糖皮质激素和长期或高剂量吸入糖皮质激素(ICS);合并曲霉致敏且规范慢阻肺治疗后仍持续喘息者或ABPA患者,专家组推荐全身糖皮质激素联合抗真菌治疗并考虑使用ICS以减少全身糖皮质激素剂量,治疗期间须密切监测向IPA或亚急性侵袭性肺曲霉病进展。

红旗征与不能漏的情况

  • 重症患者(如收治ICU及呼吸衰竭者)对广谱抗生素治疗无反应且影像学符合IPA时,可在综合评估曲霉感染风险后启动经验性抗真菌治疗,同时尽早启动病原学检查。
  • HRCT或支气管镜检查符合气道侵袭性曲霉病者,可在综合评估曲霉感染风险后启动经验性抗真菌治疗,同时尽早启动病原学检查。
  • 过去3个月内有口服或静脉糖皮质激素使用史者,可在综合评估曲霉感染风险后启动经验性抗真菌治疗,同时尽早启动病原学检查。
  • 有气道曲霉感染或定植史者,可在综合评估曲霉感染风险后启动经验性抗真菌治疗,同时尽早启动病原学检查。
  • CPA伴空洞与支气管腔相通者,全身抗真菌治疗无效或因不良反应不能耐受且手术不可行时,专家组建议考虑雾化吸入两性霉素B及空洞内注射两性霉素B或唑类(伏立康唑、伊曲康唑)以控制反复咯血。
  • 治疗期间须密切监测向IPA或亚急性侵袭性肺曲霉病进展。

研究设计与关键结果

  • 共识基于循证证据和我国临床实践情况,对慢阻肺伴肺曲霉病诊治中的重要问题提出推荐意见并构建临床诊疗路径。
  • 多数推荐证据水平低,共识未列出证据等级,强推荐和弱推荐分别表述为「推荐」和「建议」。

证据类型、等级与局限

  • 证据类型:专家共识。
  • 多数推荐证据水平低,共识未列出证据等级,强推荐和弱推荐分别表述为「推荐」和「建议」。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 对疑似慢阻肺伴IPA者应先行HRCT,CT不能除外IPA时加做痰和BALF真菌学检查,而非仅凭咳嗽、发热、呼吸困难经验性用药。
  • 对ICU或呼吸衰竭、广谱抗生素无反应且影像符合IPA者,可在综合评估曲霉感染风险后启动经验性抗真菌治疗,同时尽早启动病原学检查。
  • 慢阻肺伴IPA抗真菌疗程至少6-12周,停药需参考症状、肺部影像和微生物学结果及危险因素消除情况。
  • 稳定期慢阻肺合并CPA者应避免全身糖皮质激素和长期或高剂量ICS;慢阻肺急性加重继发IPA或亚急性侵袭性肺曲霉病者应控制糖皮质激素使用。
  • 慢阻肺伴曲霉致敏者不推荐常规启动抗真菌治疗,仅符合ABPA诊断标准者建议抗真菌治疗。

指南或共识出处

  • 慢性阻塞性肺疾病患者肺曲霉病诊治专家共识(Zhonghua Jie He He Hu Xi Za Zhi)

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

The prevalence of pulmonary aspergillosis is increasing in patients with chronic obstructive pulmonary disease (COPD) and can manifest in different forms such as invasive pulmonary aspergillosis (IPA), chronic pulmonary aspergillosis (CPA) and allergic bronchopulmonary aspergillosis (ABPA). With the variations of individual conditions such as immune status, these forms of the disease may transform into each other or even overlap. Moreover, the atypical clinical manifestations and the limited use of invasive sampling techniques have posed a challenge to the diagnosis and treatment of invasive pulmonary aspergillosis in patients with COPD. To provide recommendations for the management of pulmonary aspergillosis in patients with COPD and to construct a clinical workflow, the consensus panel reviewed the evidence and critically appraised the existing studies. As the majority of the recommendations were supported by low levels of evidence, the evidence levels were not listed in the consensus and the strong and weak recommendations were expressed as "recommend" and "suggest", respectively.Recommendations for COPD with IPA: The Panel recommends that high-resolution chest computed tomography (HRCT) be performed in patients suspected with IPA. If IPA cannot be excluded by CT scanning, mycological examination of sputum and bronchoalveolar lavage fluid (BALF) is recommended. Bronchoscopy and BALF Aspergillus-related examination are recommended in COPD patients with respiratory symptoms such as dyspnea despite the use of broad-spectrum antibiotics and systemic glucocorticoids and pulmonary infiltrates observed on chest CT. If the diagnosis is in doubt in patients with probable IPA, histopathological examination is recommended. In COPD patients with an acute infection of more than 10 days' duration, the Panel recommended the detection of Aspergillus-specific IgG antibodies in peripheral blood to aid in the diagnosis of IPA, especially in those who cannot obtain BALF. It is not recommended to initiate antifungal therapy based on clinical symptoms such as cough, fever, and dyspnea empirically in COPD patients. In critically ill patients (such as those admitted to ICU and those with respiratory failure) who are unresponsive to broad-spectrum antibiotic treatment and have imaging findings consistent with IPA, patients with HRCT or bronchoscopy findings consistent with airway invasive aspergillosis, patients with a history of oral or intravenous glucocorticoid use in the past 3 months, or patients with a history of airway Aspergillus infection or colonization, empirical antifungal therapy may be initiated after a comprehensive evaluation of Aspergillus infection risk, and at the same time, pathogen examination should be started as early as possible. Voriconazole, isavuconazole, and posaconazole are recommended as the first-line treatments for COPD with IPA. Echinocandins and amphotericin B may be used as alternative options. Antifungal treatment for COPD with IPA should be continued for at least 6-12 weeks. The duration of antifungal therapy should be determined based on clinical symptoms, pulmonary imaging, and microbiological test results. Significant lesion absorption and stabilization, as well as the elimination of related risk factors, are important references for discontinuation of treatment.Recommendations on COPD with CPA: Chest CT scan and dynamic observation are recommended for COPD with suspected CPA. Peripheral blood Aspergillus-specific IgG antibody testing is recommended in COPD patients with suspected CPA. For those who are difficult to diagnose by routine methods or need further differential diagnosis, pulmonary tissue histopathological examination is recommended. Oral itraconazole solution or voriconazole tablets are recommended as the first-line treatment options for COPD with CPA. Oral isavuconazole capsules or enteric-coated posaconazole tablets can be used as an alternative. Intravenous administration of echinocandins or amphotericin B (deoxycholate or lipid formulations) are suggested as a second-line treatment options in cases of triazole treatment failure, resistance, or intolerance. Antifungal treatment for COPD with CPA should be continued for at least 6 months, and for patients with CCPA for at least 9 months. In those with cavities communicating with the bronchial lumen, if systemic antifungal therapy is ineffective or cannot be tolerated due to adverse reactions, and surgery is also not feasible, the Panel suggests considering nebulized inhalation of amphotericin B and intracavitary injection of amphotericin B or azoles (voriconazole, itraconazole) to control recurrent hemoptysis.Recommendations on COPD with Aspergillus sensitization: When COPD patients present with refractory wheezing and/or rapid decline in lung function, it is recommended that an assessment for Aspergillus sensitization be performed, including Aspergillus-specific IgE, skin Aspergillus antigen test, Aspergillus-specific IgG, total IgE, blood eosinophil count, and sputum examination. The Panel recommends that antifungal therapy should not be routinely initiated in COPD patients with Aspergillus sensitization. For those who meet the diagnostic criteria for ABPA, antifungal therapy is suggested. The most commonly used medication is oral itraconazole solution, but other azoles such as voriconazole, isavuconazole and posaconazole enteric-coated tablets can also be chosen. The general course of antifungal therapy is 3-6 months.Recommendations on the use of glucocorticoids in COPD with pulmonary aspergillosis: In exacerbating COPD patients with secondary IPA or subacute invasive aspergillosis, the Panel suggests that the use of glucocorticoids should be controlled. For COPD patients with concomitant CPA who experience exacerbations with predominantly wheezing, it is suggested that short-term, low-dose glucocorticoids be considered on the basis of antifungal treatment to control symptoms. Glucocorticoid use for COPD exacerbations is suggested to be guided by peripheral blood eosinophil count. It is recommended to avoid systemic glucocorticoids and long-term or high-dose inhaled glucocorticoids (ICS) in stable COPD patients with concomitant CPA. In patients with concomitant Aspergillus sensitization and persistent wheezing despite standardized COPD treatment or patients with ABPA, the Panel recommends systemic glucocorticoids in combination with antifungal therapy and consideration of the use of ICS to reduce the dose of systemic glucocorticoids. Close monitoring for progression to IPA or subacute invasive aspergillosis is essential during treatment.

在慢性阻塞性肺疾病(简称慢阻肺)人群中,肺曲霉病的发病率不断上升,可表现为侵袭性感染、慢性肺曲霉病、变应性支气管肺曲霉病等多种形式;随着免疫功能等个体状态的变化,各种形式之间可互相转换甚至并存。同时,慢阻肺伴侵袭性肺曲霉病多缺乏典型表现,且部分患者有创检查受限,给诊断和治疗带来了挑战。为此,本共识基于循证证据和我国临床实践情况,对慢阻肺伴肺曲霉病诊治中的重要问题提出推荐意见,构建临床诊疗路径,期待为改善疾病管理提供参考和指引。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

参考来源

  1. [Expert consensus on the diagnosis and treatment of pulmonary aspergillosis in patients with chronic obstructive pulmonary disease]. Zhonghua Jie He He Hu Xi Za Zhi. 2024. PMID: 38955746. doi:10.3760/cma.j.cn112147-20231228-00399

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。